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generic risperidone, although there were prescribing restrictions 
for long-acting injectable risperidone in Austria and Belgium. As a 
result, no change in its utilization after generics reimbursed. Overall, 
high utilization of generic versus originator risperidone once avail-
able. Appreciable reduction in the price of generic risperidone once 
it became available limited the extent of any subsequent increase in 
AAP expenditure despite increasing utilization.
Conclusion: No apparent effectiveness or safety problems with 
generic risperidone. Authorities cannot rely on a spillover effect from 
other disease areas to change physician prescribing habits, exacer-
bated on this occasion by the need to tailor treatment approaches 
with different AAPs having different mechanisms of action and 
appreciable variability in their effectiveness and side-effects between 
patients Consequently, specific demand-side measures are needed to 
encourage the prescribing of generic AAPs first line where appropri-
ate, exacerbated by the complexity of these disease areas. Likely 
in any event that there will be limited influence of any measures 
in changing subsequent physician prescribing habits when manag-
ing patients with schizophrenia or BPD compared with acid-related 
stomach disorders or hypercholesterolemia as a greater need to tailor 
treatments. Generally no specific measures planned by these authori-
ties to influence future prescribing habits with further generic AAPs 
becoming available.
Financial Source: Study part funded by a grant from the Karolinska 
Institutet. Majority of authors employed by health authorities or are 
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Introduction: Antidepressive drug venlafaxine belongs to the seroto-
nine and norepinephrine reuptake inhibitors. It is primary metabo-
lized by CYP2D6 to its active metabolite O-desmethylvenlafaxine 
and by CYP3A4 to N-desmethylvenlafaxine. The range 0.3-5.2 for 
O-desmethylvenlafaxine/venlafaxine ratio was estimated for exten-
sive and intermediate metabolizers.
Patients (or Materials) and Methods: There is described intoxication 
of woman (41 years) treated by combination therapy venlafaxine 
150 mg/d, mianserine 60 mg/d, clonazepam 1 mg/d, and olanzapine 
10 mg/d. TDM of these substances was provided using LC-MS/MS 
method to estimate phenotype of venlafaxine and to compare with 
genotype.
Results: On admission, toxic plasma level of venlafaxine was 
found (2638 ng/mL) and after reduction of the dose to 75 mg/d 
plasma level was estimated in therapeutic range (364 ng/mL). The 
ratio O-desmethylvenlafaxine/venlafaxine was estimated between 
0.005 and 0.016 showing poor metabolizator. Genetic examina-
tion detected homozygotes deletion of the gene CYP2D6 *5/*5 
and explained phenotype. Plasma level of olanazapine was found 
in therapeutic range, plasma level of clonazepam was found below 
therapeutic range.
Conclusion: The ratio of the metabolite to the parent substance (phe-
notype) allows us to detect any deviation in the metabolism of drugs 
which can be subsequently explained by determination of genotype. 
Therapeutic drug monitoring contributes to the optimalization of 
pharmacotherapy in the case of psychotropic drugs.
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Introduction: Alzheimer’s disease is a neurodegenerative disorder 
associated with depletion of acetylcholine in neuronal terminals with 
increased oxidative stress in cells resulting in neuroinflammation. 
Inhibiting acetylcholine esterase (AchE) increases the concentration of 
neuronal acetylcholine. Further xanthine oxidase (XO) is an important 
source of free radicals and plays an important role in oxidative stress 
associated with neuroinflammation. Thus, a dual acting inhibitor of 
AchE & XO can be a good candidate for the treatment of neurodegen-
erative disorders like Alzheimer’s. The aim of this study is to explore the 
inhibitory potential of 4-methyl esculetin against both AchE and XO.
Patients (or Materials) and Methods: The X-ray crystal structures of 
rivastigmine bound to acetylcholinesterase (AChE) (PDB 1GQR) and 
quercetin bound to xanthine oxidase (XO) (PBD 3NVY) were obtained 
from the Protein Data Bank. The proteins were prepared for the dock-
ing studies with the Protein Preparation Wizard in the Schrödinger Suite 
2012 (Schrödinger LLC, USA). The ligand 4-methyl esculetin (4-ME) 
was docked into the target proteins AhcE and XO and binding poses 
ranked by Glide Score (SP). The inhibitory activity of 4-ME towards 
AchE was measured by an in vitro assay using rat brain AchE, and inhi-
bition of XO was done using crude XO obtained from rat liver tissue.
Results: The docking studies revealed that 4-methyl esculetin binds 
in a similar fashion to both AChE and XO and makes identical inter-
actions as the native ligands (rivastigmine for AchE & quercetin for 
XO). The Glide Score for 4-methyl esculetin (–6.97 for AchE and 
–7.78 for XO) also does not differ significantly in both targets; hence, 
it can be said with confidence that 4-ME should exhibit comparable 
potency towards the 2 protein targets. This is well substantiated by 
in vitro enzyme assays that confirmed the equal inhibitory properties 
of 4-ME towards both the target viz. AchE and XO. Kinetic studies 
showed that 4-ME acts as a competitive inhibitor against XO while 
exhibiting mixed type inhibition toward AchE.
Conclusion: The results of the present study indicate that a combi-
nation of both AchE and XO inhibitory properties for 4-ME could 
make it a useful asset in the management of Alzheimer’s disease.
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Introduction: Aluminium is a potent neurotoxin and has been associ-
ated with Alzheimer’s disease (AD). Prolonged aluminium exposure 
induces oxidative stress and contributes to the development of neu-
rodegeneration. Current treatment modalities for AD provide only 
symptomatic relief, thus necessitating the development of new drugs 
with multiple targeting strategies. The aim of the study was to dem-
onstrate the protective effect of chronic administration of 4-methyl-
esculetin (4-ME) against aluminium-induced cognitive dysfunction 
and oxidative damage in rats.
Patients (or Materials) and Methods: Wistar rats (180–200 g) were 
divided into 6 groups (n = 6). Group I was the control group and 
group II received aluminium chloride (100 mg/kg PO) for a period 
of 42 days. Group III and IV received 4-ME (50 and 100 mg/kg PO) 
daily 1 hour before aluminium chloride (100 mg/kg PO) for 42 days 
while groups V and VI received only 4-ME (50 and 100 mg/kg PO) 
daily for 42 days. On the 21st and 42nd day, behavioral studies 
